1. Outlook Therapeutics granted stock options for 150,000 shares at $2.01 each. 2. Stock options incentivize new employees, highlighting company growth plans. 3. ONS-5010/LYTENAVA is under investigational status for U.S. approval. 4. Company's treatment launched in Germany and the UK for wet AMD.
FAQ
Why Neutral?
While stock options might imply growth potential, they do not guarantee immediate price increases. Previous instances where companies granted options showed mixed impacts on stock prices.
How important is it?
The employee stock options indicate company growth aspirations, yet they aren't substantial news. The investigational status of ONS-5010 could impact future valuations significantly.
Why Short Term?
The granting of stock options typically influences employee retention and morale quickly. However, tangible impacts on stock price will depend on broader market responses and approval progress.
ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees.
The above-described awards were granted as an inducement material to the employees entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retinal diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD (wet age-related macular degeneration). Outlook Therapeutics commenced the commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the treatment of wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
